At a glance
ClinicalIndex Comparison RecordPhase 2Recruiting· 120 target
Drug / intervention
Crizotinib +1 moredrug
Likely dose
Crizotinib 250mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
NCT04322578Phase 2RecruitingUpdate OverdueUpdated 24mo ago · Completion was 15mo agoEnrollment Stalled
Long Recruiting
Update Overdue
Crizotinb or Standard Chemotherapy in Met Exon 14 Skipping Advanced Non-small Cell Lung Cancer
In Brief
A Phase 2 clinical trial evaluating Crizotinib and Pemetrexed for Non-small Cell Lung Cancer. Currently recruiting, targeting 120 participants across 1 site.
Signals
Enrollment appears stalled
Detailed Summary
This study aims to explore the efficacy and safety of Crizotinb or Standard Chemotherapy in Met exon 14 skipping Advanced Non-small Cell Lung Cancer
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-small Cell Lung Cancer
CountriesChina
Collaborators--
Timeline
Phase 2RecruitingOverdue
202120222023202420252026
Enrollment StartMar 2020
First PostedMar 2020
Primary CompletionMar 2025
Study CompletionMar 2026
TodayJul 2026
First PostedMar 26, 2020
Enrollment StartMar 24, 2020
Primary CompletionMar 24, 2025
Study CompletionMar 24, 2026
TodayJul 1, 2026
Enrollment to primary: 5 yearsPosted 6.3 years ago
Interventions
Crizotinibdrug
Crizotinib 250mg po bid. Savolitinib 300mg po, qd.
Pemetrexeddrug
Pemetrexed, 500mg/m2, ivgtt erery 21day.